Haemonetics Corp. slid after it said quarterly earnings fell 46 percent. The Braintree company, which makes and sells blood-management systems, earned $9.9 million, or 19 cents per share, in the quarter ended in December, compared to $18.3 million, or 36 cents, a year earlier. Administrative and other expenses rose 41 percent; research and development costs rose about 15 percent. Haemonetics said it expects its new OrthoPat Advance system to drive fiscal 2014 growth.
January 31, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢